CSPC Pharmaceutical Group Ltd. has received FDA clearance of its IND for a phase I trial of its antibody-drug conjugate CPO-301 for the treatment of advanced lung cancer with alterations in the EGFR gene or EGFR over-expression.

Cabaletta Bio Inc.’s IND application for CABA-201, a 4-1BB-containing fully human CD19-chimeric...

Comanche Biopharma Corp. has received IND clearance from the FDA to conduct a first-in-human study of CBP-4888, its novel, small interfering ribonucleic acid (siRNA) therapy to treat pre-eclampsia.

Eloxx Pharmaceuticals Inc. has filed an IND application with the FDA for ZKN-013 for the...